The effectiveness of anti-programmed cell death 1 (PD1) immunotherapy, a promising pathway (Wang et al., 2019) in the treatment of gliomas, is correlated with the expression of the programmed death ligand 1 (PD-L1) and the tumor immune microenvironment cell components (Yang et al., 2021; Yao et al., 2021). This evidence concerns the gene CD274 and neoplasm.